Cell Therapeutics' Pacritinib Phase III Program Takes Off
By Catherine Shaffer
Staff Writer
Staff Writer
Wednesday, January 9, 2013
Cell Therapeutics Inc., of Seattle, began a much-anticipated Phase III trial for its JAK2 inhibitor, pacritinib, in myelofibrosis. It licensed the drug from Singapore-based S*Bio Pte Ltd. in April for $30 million up front and up to $132.5 million in regulatory and sales milestones.
To continue reading subscribe now to Latest News
Learn More about Latest News
Already a subscriber? Sign In or Buy now to activate your subscription
BioWorld | 3525 Piedmont Road
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Part of Thompson Media Group LLC
Free Ezine
Sign up for Perspectives FREE e-mail newsletter.
Customer Service: In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-404-262-5423
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Outside the U.S.: 1-404-262-5423
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Copyright @ 2013 AHC Media. Reproduction, reposting content is strictly prohibited.